3D conformal hypofractionated radical radiotherapy in early glottic cancer  by Amado, Ana Cristina et al.
R3
r
A
a
b
a
A
R
R
1
A
K
H
L
E
T
1
L
n
1
hreports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 261–264
Available  online  at  www.sciencedirect.com
jou rn al hom ep age: ht tp : / /www.e lsev ier .com/ locate / rpor
eview
D  conformal  hypofractionated  radical
adiotherapy in  early  glottic  cancer
na Cristina Amadoa,∗, Laurentiu Bujora, Isabel Monteiro Grilloa,b
Radiotherapy Department, Hospital de Santa Maria – Centro Hospitalar Lisboa Norte, Lisbon, Portugal
Medical Faculty of Lisbon, Lisbon University, Lisbon, Portugal
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 22 August 2012
eceived in revised form
1 March 2013
ccepted 23 April 2013
eywords:
ypofractionation
arynx
arly glottic cancer
1–T2
a  b  s  t  r  a  c  t
Aim: The purpose of this study was to evaluate acute and late toxicity and the locoregional
control in patients treated with hypofractionated radical radiotherapy 2.25 Gy/fraction/day
for  early glottic carcinoma.
Materials and methods: A retrospective analysis was performed of 27 patients, stage T1–T2
N0  glottic squamous cell carcinoma, that underwent radical RT from April 2008 to October
2011.  The mean age was 64.6 years (range 36–81). Seventeen patients were staged T1a, 3
patients T1b and 7 patients T2. All patients were 3D planned and treated in a 6 MV LINAC,
2.25 Gy/fraction/5 days per week, to a total dose between 63 Gy and 67.5 Gy. Biological Effec-
tive Dose (BED (˛/  ˇ = 10)) ranged from 77.18 Gy to 82.69 Gy and EQD2 from 64.31 Gy to 68.91 Gy.
Patients were evaluated in periodic follow-up. Toxicity was evaluated according to RTOG
Toxicities Scales.
Results: With a median follow-time of 24.7 months (range 3.6–44.2 months), no evidence of
locoregional recurrence was observed. The treatment was well tolerated and no unsched-
uled interruptions in treatments for toxicity were documented, with the median overall
treatment time of 41 days (range 38–48). Only grades 1 and 2 acute toxicity were observed
and no evidence of severe late toxicity.
Conclusion: The authors believe that this moderately hypofractionated scheme can provide
a  good locoregional control for T1–T2 glottic carcinomas with no increase of toxicity. As thelimitation of this work is the reduced number of patients and the lack of long term follow-
up,  the authors hope to update this retrospective study in the future in order to improve the
power of the results.
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terior commissures. It is the most common laryngeal cancer
and it has the most favorable prognosis, mainly if diagnosed
early.
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Persistent hoarseness is the usual presenting symptom of
glottic carcinoma present even in small lesions, which brings
patients (pts) to medical attention and allows a sooner diag-
nosis, as the lesions are easily visible by laryngoscopy and
reached for a biopsy. About 70% of all cases have localized
disease at diagnosis.2,3
Tobacco has a major role in the development of the dis-
ease, with alcohol consumption and occupational exposure
(diesel fumes, sulfuric acid, coal dust and machining ﬂuids)
being other main risk factors.
Squamous cell carcinoma (SCC) is the most common histo-
logical type of glottic cancer, usually being well differentiated.
In early lesions lymph node involvement is rare (<3%) due to
the lack of lymphatic drainage of the glottis.1,2
The goal of the conservative treatment in early glottic can-
cer (EGC) is the control of the disease while maintaining a good
quality of the essential laryngeal functions: phonation and
swallowing. Ideally, EGC (T1–T2 N0) should be managed with a
single modality either microsurgery or deﬁnitive Radiotherapy
(RT). RT is considered gold standard in some Institutions and in
northern European countries,4–8 reserving surgery for salvage
of failures. The local control rate with deﬁnitive radiotherapy
is approximately 83–95% for T1 and 70–80% for T2 lesions.2,9,23
There is no consensus for the best fractionation schedules
for deﬁnitive RT in EGC. Fractionation policy for early laryngeal
cancer differs between reporting institutions, varying largely
from very hypofractionated schedules like 50–52.5 Gy/16
fractions over 21 days currently employed in the UK6 to con-
ventional fractionated schemes.
Since there is level 1 evidence that 2.25 Gy/fraction is better
than conventional fractionation, the aim of our analysis was
to evaluate the acute (AT) and late toxicity (LT) as well as LRC
in the pts treated for EGC in our Institution.
A recent Japanese prospective trial randomized pts with
T1 N0 SCC of the glottis to deﬁnitive RT at 2 Gy/fraction or
2.25 Gy/fraction. The 5-year local control rates were 77% with
2 Gy/fraction vs. 92% with 2.25 Gy/fraction (p < 0.004) and no
difference in either AT or LT.11
2.  Materials  and  methods
A retrospective analysis was performed of twenty-seven pts,
stage T1–T2 N0 glottic SCC, that underwent radical RT from
April 2008 to October 2011 in the Department of Radiation
Oncology of Hospital de Santa Maria – CHLN. None of these
patients received elective nodal treatment or chemotherapy.
The mean age was 64.6 years (range 36–81); 22 males and 5
females. All pts had SCC proven histology; 17 pts with T1a
stage, 3 pts T1b and 7 pts T2 Stage; 19 pts (70%) were heavy
smokers. All pts were 3D planned, in a supine position with
hyperextended neck and immobilized with a head and shoul-
ders thermoplastic mask and were treated with a 2 or 3 ﬁeld
technique in a 6 MV  LINAC, 2.25 Gy/fraction, 5 days per week,
to a total dose between 63 Gy and 67.5 Gy. Biological Effective
Dose (BED (˛/  ˇ = 10)) ranged from 77.18 Gy to 82.69 Gy and EQD2
from 64.31 Gy to 68.91 Gy. T1 lesions were treated to a total
dose of 63 Gy and T2 lesions to 65.25 Gy; just one T1 patient
was treated with 67.5 Gy to compensate a treatment interrup-
tion due to a LINAC scheduled maintenance and 2 bankingiotherapy 1 8 ( 2 0 1 3 ) 261–264
holidays. The clinical target volume (CTV) included all the lar-
ynx mucosa with the ﬁelds limits superiorly up to the top of
the thyroid cartilage and caudally at the bottom of the cricoids,
cartilage anteriorly and laterally, and posteriorly the posterior
mucosa or the anterior edge of the vertebral body, No GTV was
delineated and the margin to the PTV was 5 mm isotropically.
The OARs delineated were the spinal cord – maximum dose
45 Gy and esophagus – maximum dose 105% of prescribed dose
and median <35 Gy, both absolute doses as equivalent doses
for 2 Gy/fraction.
Pts were evaluated in periodic follow-up that included
a disease speciﬁc history with neck examination to detect
enlarged nodes, panendoscopy and, if clinically indicated, cer-
vical computed tomography to conﬁrm LRC. Toxicity, acute
and late, was evaluated according to RTOG Toxicities Scales.
3.  Results
With a median follow-time of 24.7 months (range 3.6–44.2
months) no evidence of loco-regional recurrence was
observed. Two pts died 2.5 and 17 months after the end of
the treatment, both for other causes than glottic cancer (post-
operatory complication for other head and neck cancer and
chronic obstructive lung disease, respectively) and one patient
developed a synchronous cancer (oropharyx) at 2.5 months
of follow-up. No other second primaries detected. All other
patients had at least 5 months of follow-up.
The treatment was well tolerated and no unscheduled
interruptions were documented, with the median overall
treatment time (OTT) of 41 days (range 38–48), with 92.6%
of the pts (25 pts) with OTT ≤ 43 days. Grades 1 and 2 acute
dysphagia were observed in 3 (11%) and 19 pts (70%), respec-
tively; grades 1 and 2 acute radiodermitis in 11 pts (41%); acute
odynophagia grade 2 in 16 pts (59%). No AT grade 3 were
observed. No evidence of severe LT: 6 pts (22%) with grade 1
hoarseness, 3 pts (11%) with grade 1 dysphagia and 1 pt (4%)
with xerostomia.
No evidence of distant metastases was observed during
the follow-up time and there was no need for surgery, tra-
cheostomy or gastrostomy in any pts of this study.
4.  Discussion
In general, EGC (T1–T2 N0) are managed with a single modal-
ity, but there are no randomized trials comparing surgery to
RT to laser resection. However, in spite of having similar local
control, survival and preservation of the larynx functions, it
seems that RT or laser resection are better in voice quality
preservation than partial laryngectomy. For larger T2 lesions
or impaired cord mobility, laser does not present so good
results in voice preserving as RT, also having a high rate of
recurrences; so RT becomes the best modality in non-selected
EGC pts.9
The shorter overall treatment time and larger fraction
size could be advantageous in radiobiology of well differen-
tiated tumors. There are many  studies which demonstrate
that external beam RT schedules using a fraction size greater
than 2 Gy, in EGC, result in equivalent or even better local con-
trol and disease-free survival than longer schedules and no
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15. Reddy SP, Hong RL, Nagda S, et al. Effect of tumor bulk on
local control and survival of patients with T1 glottic cancer: areports of practical oncology and 
ifference in AT and LT.8,10–13 When external beam RT is used
s the primary treatment modality in pts with EGC, hypofrac-
ionated regimens should be used, without chemotherapy or
rophylactic treatment of the neck nodes, but many  schemes
f hypofractionation are described in the literature.
According to the University of Florida – San Francisco,9 in
ur Department, we  began to use 2.25 Gy/fraction instead of
onventional scheme in EGC, in order to shorten OTT trying to
void repopulation of cells. This fraction size was also proved
o be more  effective than conventional one in a Japanese ran-
omized trial – Yamazaki et al.11
The small volumes irradiated allowed the use of hypofrac-
ionation without the concern of severe toxicities, as it
iminished the normal tissues of the irradiation ﬁeld. Some
uthors correlated dosimetry parameters, such as mean laryn-
eal dose of V50 Gy with late laryngeal toxicity.24,25 The aim of
ur study was not to assess such parameters since our late
oxicities were only grade 1.
Our results are very similar to those published in the liter-
ture, showing that hypofractionation have excellent results
nd cures a high percentage of pts with EGC. For T2 lesions
ur results tend to be better in local control than those
eported in the literature, although we still have a short
ollow-up time. In 92.6% of pts (25 pts) we accomplished
he OTT ≤ 43 days, that is the cut-off for no inﬂuence on
he local control in T2 lesions in a published trial by Uni-
ersity of California,8 using the same fractionation scheme
s ours. Short OTT brings beneﬁt in EGC local control, as
lready proved in many  trials,8,14–19 which can be explained
y the fact of almost all cases being well differentiated SCC,
aving a faster doubling time and a rapid capacity of repop-
lation, which was documented in CHART and DAHANCA
tudies.6,19–22
Regular follow-up is needed after a potentially curative
reatment to ensure that local control is achieved for a long
ime. Almost all local recurrences will occur in the ﬁrst four
ears, mainly in the ﬁrst year, but continuously follow-up is
equired, especially in pts who maintain their smoking and
rinking habits.
The fact of no documented local failure within the follow-
p time, and no need for surgery, tracheostomy or gastrostomy
ube could be related with the reduced number of pts and the
ack of long term follow-up, which are the main limitations of
his work.
.  Conclusions
he authors believe that for T1–T2 glottic carcinomas, deﬁni-
ive RT with 2.25 Gy/fraction can provide a good term local
ontrol and survival with the preservation of the normal struc-
ure and function of the larynx.
An important limitation of this study relates to its ret-
ospective nature with its inherent biases, to the few pts
nvolved and the lack of long term follow-up. Due to the
ood results in terms of LRC and toxicity and a shorter
TT, this fractionation scheme became a standard treat-
ent in our Institution. We  hope to update this retrospective
tudy in the future in order to improve the power of our
esults.
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